Table 1.
Participant overview
| Total cohort | Control | MCI | AD | |
|---|---|---|---|---|
| Urine | ||||
| Participants | 556 | 171 | 209 | 176 |
| Male/female | 269/287 | 83/88 | 95/114 | 91/85 |
| Mean age (SD) | 76.24 (5.76) | 75.85 (5.17) | 76.33 (6.03) | 76.53 (5.99) |
| MMSE score | 25.67 (4.59) | 28.73 (1.92) | 26.86 (2.75) | 21.17 (4.87) |
| CDR | 0.56 (0.51) | 0.07 (0.18) | 0.49 (0.08) | 1.10 (0.54) |
| Reported SSRI medication | 43 | 4 | 16 | 23 |
| Serum | ||||
| Participants | 354 | 86 | 165 | 103 |
| Male/female | 165/189 | 44/42 | 71/94 | 50/53 |
| Mean age | 76.95 (6.13) | 75.97 (5.67) | 77.50 (6.49) | 76.91 (5.84) |
| MMSE score | 25.57 (4.37) | 28.80 (1.99) | 26.73 (2.24) | 21.06 (4.79) |
| CDR | 0.59 (0.54) | 0.04 (0.16) | 0.49 (0.11) | 1.16 (0.55) |
| Reported SSRI medication | 30 | 1 | 11 | 18 |
Overview of the sample cohort used in the study. SSRI selective serotonin reuptake inhibitor, MCI mild cognitive impairment, AD Alzheimer’s disease, MMSE Mini-Mental State Examination score, CDR Clinical Dementia Rating